Business
Conference Attendance and Presentation
Conference Attendance and Presentation.
About this update from Physiomics Plc
[{"type":"text","content":"\n \nRNS Number : 3576T Physiomics PLC 20 March 2019 \n\n \n20th March 2019\nPhysiomics plc \n(\"Physiomics\") or (\"the Company\")\n \n \nConference attendance and presentation\n \nPhysiomics to present on personalised medicine and Virtual Tumour™ developments at AACR 2019 meeting\n \nPhysiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it is participating in the American Academy of Cancer Research (\"AACR\") Annual Meeting 2019, taking place in Atlanta, Georgia, 29th March to 3rd April. The company will for the first time be presenting on two new topics arising from client and grant funded projects.\nPhysiomics will have a significant presence at the conference including a stand in the main meeting hall (booth #1851). The Company plans to use the opportunity of the conference to meet with both current as well as potential future clients.\nIn addition, the Company will be presenting two original posters in the session \"PO.BSB02.01 - Convergence Science for Therapeutics and Precision Medicine\"-Section 30, scheduled 31st March 2019, 1:00 PM - 5:00 PM:\n· A precision dosing application for prostate cancer chemotherapy (Abstract #677)\nThis is our first tool based on AI (machine learning) technologies. Currently dosing of docetaxel in prostate cancer is based on population averages, leading to effective under or over dosing in a significant number of patients. Our tool could, if approved, provide information that could assist clinicians in adapting chemotherapy dosing for individual patients. This offers the possibility of enhancing both the safety and efficacy of an existing standard of care without the costs typically associated with a new pharmaceutical product.\n· Predicting the effect of radiotherapy on tumour growth inhibition and time to progression in head and neck cancer (Abstract #680)\nOver recent years, driven by a number of actual client projects, we have extended our Virtual Tumour™ technology from a tool primarily used to predict preclinical tumour growth inhibition into one that can also help clients understand the likely response to their drug(s) in the clinic. The most recent evolutio...